The partnership will investigate Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease. These medicines are designed to directly increase the flow of lipids from
The grant is designed to help VistaGen progress its lead drug candidate AV-101 (4-Cl-KYN) through developmental trials. VistaGen will complete preclinical efficacy studies for AV-101 for use as
The so-called Breath-5 study evaluated the use of Tracleer (bosentan) in patients with Eisenmenger’s syndrome, a progressive heart condition that occurs in people who have a congenital heart
The technologies were developed at the Imperial College London, the base from which NovaThera was originally formed. Pharming and NovaThera are to collaborate on combining NovaThera’s proprietary biomaterial
NPS submitted the application on May 10, 2005, and the FDA has now made a threshold determination that the Preos NDA is sufficiently complete to permit a substantive
HCT 1026 is a nitric oxide-donating derivative of flurbiprofen, an anti-inflammatory drug useful in the treatment of arthritis. These results demonstrate the potential utility of nitric oxide-donation in
If approved for this indication, Femara will become the only breast cancer treatment available to significantly reduce the risk of recurrence in the post-surgery setting as well as
In controlled clinical trials, patients taking a Roche anti-amyloid drug candidate for Alzheimer’s disease will be monitored clinically for drug response using GE’s positron emission tomography (PET) diagnostic
Sorafenib was accepted by the FDA into the Pilot 1 Program for continuous marketing applications. The Pilot 1 Program was designed for therapies that have been granted “fast
According to the two companies, the new platform will enable pharmaceutical companies to deliver clinical-based education about new drugs and therapies to physicians worldwide, in an attempt to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.